Neferine increases STI571 chemosensitivity via inhibition of P-gp expression in STI571-resistant K562 cells

Leukemia and Lymphoma

Volumn 52, Issue 4, 2011, Pages 694-700

  Qin, Qun ^a,b   Chen, Xiao Ping ^b   Yang, Zhou Sheng ^a,b   Xiao, Yu Hang ^a,b   Min, Hui ^a,b   Li, Yuan Jian ^b  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

drug resistance; Leukemia; neferine; P gp protein; STI571

Indexed keywords

GLYCOPROTEIN P; IMATINIB; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; NEFERINE; VERAPAMIL;

ARTICLE; CELL GROWTH; CELL PROLIFERATION; CHEMOSENSITIVITY; CONCENTRATION RESPONSE; CYTOTOXICITY; DRUG ACCUMULATION; DRUG POTENTIATION; DRUG RESISTANCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

BENZYLISOQUINOLINES; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; K562 CELLS; P-GLYCOPROTEIN; PIPERAZINES; PYRIMIDINES; RNA, MESSENGER;

EID: 79953193096     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2010.550075     Document Type: Article

References (22)

1. Takara K, Sakaeda T, Okumura K. An update on overcoming MDR-1-mediated multidrug resistance in cancer chemother-apy. Curr Pharm Des 2006;12:273-286.
2. Lee CH. Reversing agents for ATP-binding cassette drug transporters. Methods Mol Biol 2010;596:325-340.
3. Goldman JM, Melo JV. Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344: 1084-1086. (Pubitemid 32267980)
4. Thiesing JT, Jones O, Kolibaba KS, Druker BJ. Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl positive cells. Blood 2000;9:3195-3199.
5. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-1037. (Pubitemid 32267972)
6. Gorre ME, Mahammed M, Ellwood K, et al. Clinical resistance to STI571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293:876-880. (Pubitemid 32743979)
7. Mahon FX, Deininger MW, Schultheis B, et al. Selection and characterization of BCR-ABL positive cell lineswith differen-tial sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanism ofresistance. Blood 2000;96:1070-1079. (Pubitemid 30616875)
8. Le Coutre P, Tassi E, Varella-Garcia M, et al. Induction of resistance to the Abelson inhibitor STI 571 in human leukemic cells through gene amplification. Blood 2000;95: 1758-1766. (Pubitemid 30120840)
9. Tipping AJ, Mahon FX, Lagarde V, Goldenman JM, Melo JV. Restoration of sensitivity to STI571 in STI571 resistant chronic myeloid leukemia cells. B1ood 2001;98:3864-3867.
10. Osborn M, Hughes T. Managing imatinib resistance in chronic myeloid leukaemia. Curr Opin Hematol 2010;17: 97-103.
11. Lehnert M, Dalton WS, Roe D, Emerson S, Salmon SE. Synergistic inhibition by verapamil and quinine of P-glyco-protein-mediated multidrug resistance in a human myeloma cell line model. Blood 1991;77:348-354.
12. Takara K, Sakaeda T, Tanigawara Y, et al. Effects of 12 Ca2+ antagonists on multidrug resistance, MDR-1 mediated trans-port and MDR-1 mRNA expression. Eur J Pharm Sci 2002; 16:159-165. (Pubitemid 34786450)
13. Engi H, Hohmann J, Gang G, et al. Chemoprevention and inhibition of P-glycoprotein in cancer cells by Chinese medicinal herbs. Phytother Res 2008;22:1671-1676.
14. Qian JQ. Cardiovascular pharmacological effects ofbisbenzy-lisoquinoline alkaloid derivatives. Acta Pharmacol Sin 2002;23:1086-1092.
15. Ye ZG, Wang JH, Sun AX, et al. Poteintation ofvincristine-induced apoptosis by tetrandrine, neferine and dauricine in the human mammary MCF-7 multidrug-resistant cells. Yao Xue Xue Bao 2001;36:96-99.
16. Cao JG, Tang XQ, Shi SH. Multidrug resistance reversal in human gastric carcinoma cells by neferine. World J Gastro-enterol 2004;10:3062-3064.
17. Ai XH, Tang XQ, Liu YP, Liu HQ, Dong L. Effect of neferine on adriamycin-resistance of thermotolerant hepato-carcinoma cell line HepG2/thermotolerance. Ai Zheng 2007; 26:357-360.
18. Qi J, Peng H, Gu ZL, Liang ZQ, Yang CZ. Establishment of an imatinib resistant cell line K562/G01 and its characteriza-tion. Zhonghua Xue Ye Xue Za Zhi 2004;25:337-341.
19. Ricardo P. Multidrug resistance retrospect and prospects in anti-cancer drug treatment. Curr Med Chem 2006;13:1859-1876.
20. Frame D. New strategies in controlling drug resistance. J Manag Care Pharm 2007;13(Suppl. A):S13-S17. (Pubitemid 350130894)
21. Stromskaya TP, Rybalkina1 EY, Kruglov SS, et al. Role of P-glycoprotein in evolution of populations of chronic myeloid leukemia cells treated with imatinib. Biochemistry 2008;73: 29-37. (Pubitemid 351653320)
22. Davidson A, Dick G, Pritchard Jones K, Pinkerton R. EVE/cyclosporin (etoposide, vincristine, epirubicin with high dose cyclosporin) chemotherapy selected for multi-drug resistance modulation. Eur J Cancer 2002;38:2422-2427. (Pubitemid 35387495)